&Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

&Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Buy	16,203 +2,226	+16%	+$30.5K	﹤0.01%	2173
2026 Q1	$174K	Buy	+13,977	New	+$188K	﹤0.01%	2276

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

&Partners's AMRX Position: Q2 2026 in Review

&Partners increased its Amneal Pharmaceuticals (AMRX) stake by 16% in Q2 2026, buying an estimated $30.5K and bringing the position to 16,203 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2173.

&Partners first reported a position in AMRX in Q1 2026 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

&Partners held 16,203 shares of Amneal Pharmaceuticals worth $280K as of Q2 2026.
&Partners bought 2,226 Amneal Pharmaceuticals shares in Q2 2026, an estimated $30.5K.
Amneal Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2173 holding.
&Partners first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.